CIK 0001023024
- Large accelerated filer
ANI PHARMACEUTICALS INC
Sign in to watch- Ticker
- ANIP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 582301143
- Phone
- +1 609-759-1810
- Business address
- 104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, NJ, 08540
- Former names
- BIOSANTE PHARMACEUTICALS INC, BEN ABRAHAM TECHNOLOGIES INC
- 4 Planned sale SR. VP, GENERAL COUNSEL & SEC. sold 250 shares at $56.04 ($14,010)
- 4 Planned sale HEAD OF R&D, COO-NOVITIUM OPS sold 25,216 shares at an average $56.17 ($1,416,466)
- 4 Planned sale HEAD OF R&D, COO-NOVITIUM OPS sold 24,784 shares at an average $55.29 ($1,370,305)
- 4 Planned sale SR. VP, GENERAL COUNSEL & SEC. sold 250 shares at $56.43 ($14,108)
- 4 Planned sale HEAD OF R&D, COO-NOVITIUM OPS sold 50,000 shares at an average $52.55 ($2,627,250)
- 4 Planned sale SR. VP, GENERAL COUNSEL & SEC. sold 250 shares at $49.21 ($12,303)
- 4 Planned sale HEAD OF R&D, COO-NOVITIUM OPS sold 13,000 shares at $51.00 ($663,000)
- 4/A Planned sale HEAD OF R&D, COO-NOVITIUM OPS sold 37,000 shares at an average $53.00 ($1,961,148)
- 4 Open-market sale SVP, CHIEF HR OFFICER sold 2,622 shares at $53.81 ($141,090)
- 4 Planned sale HEAD OF R&D, COO-NOVITIUM OPS sold 36,190 shares at an average $53.00 ($1,918,080)
- 4 Planned sale SR. VP, GENERAL COUNSEL & SEC. sold 250 shares at $52.03 ($13,008)
- 4 Open-market sale HEAD OF RARE DISEASE sold 3,000 shares at $52.47 ($157,410)
- 4 Planned sale HEAD OF R&D, COO-NOVITIUM OPS sold 25,000 shares at an average $57.75 ($1,443,869)
- 4 Planned sale HEAD OF R&D, COO-NOVITIUM OPS sold 25,000 shares at an average $57.96 ($1,449,036)
- 4 Planned sale SVP - CORP. DEV. & STRATEGY sold 20,000 shares at $56.48 ($1,129,600)
- 4 Planned sale HEAD OF R&D, COO-NOVITIUM OPS sold 50,000 shares at an average $61.81 ($3,090,617)
- 4 Shares withheld for taxes SVP, CHIEF HR OFFICER gave up 1,486 shares (to pay taxes)
- 4 Shares withheld for taxes PRESIDENT & CEO gave up 3,646 shares (to pay taxes)
- 4 Planned sale SVP - CORP. DEV. & STRATEGY sold 20,000 shares at $64.70 ($1,294,000)
- 4 Open-market sale HEAD OF R&D, COO-NOVITIUM OPS sold 50,000 shares at an average $63.22 ($3,160,750)
Page 12 of 42 · 835 filings